Oncology Accelerates In China As Large Makers Hunt For Assets
Half Of IND Filings
New regulatory measures shorten clinical trial approval times and usher in busy deal-making between large makers and smaller biotechs outside China.

New regulatory measures shorten clinical trial approval times and usher in busy deal-making between large makers and smaller biotechs outside China.